Everything You Need To Know About Retatrutide in 2026 (WATCH BEFORE TAKING)

Key wellness strategies, self-care & productivity takeaways

1) Don’t assume “stronger appetite suppression” is the only route to weight loss

• Retatrutide may create an “appetite paradox.” Some people report less appetite suppression than with tirzepatide, yet still lose more weight.
• Suggested reason: retatrutide may promote fat mobilization/oxidation through glucagon signaling, including increased ketone production (e.g., beta-hydroxybutyrate).
  • Result: weight loss can occur even when hunger feels more “normal.”

2) Choose the medication mechanism based on your main struggle (individualized fit)

• If your main challenge is food noise / constant hunger:
  • subtitles suggest tirzepatide may be the better fit due to stronger hunger suppression.
• If you have significant metabolic dysfunction (e.g., insulin resistance, fatty liver, central obesity):
  • subtitles suggest retatrutide’s multi-pathway approach (GLP-1 + GIP + glucagon) may be a better match.

3) Track progress with “metabolic-first” metrics—not just the scale

• Consider waist circumference and clothing fit as proxies for visceral fat changes, not only body weight.
• Body composition focus (as described in the subtitles):
  • Retatrutide is described as reducing visceral fat substantially (with reported ranges in the subtitles).
  • Muscle preservation is implied as part of “still losing while maintaining muscle mass.”

4) Use lipid markers to understand cardiovascular risk improvements

The subtitles claim retatrutide trials show improvements such as:

• Triglycerides down (reported up to ~41%)
• ApoB down (reported up to ~24%)
• Non-HDL cholesterol down (reported up to ~27%)

Takeaway: addressing metabolic dysfunction may improve lipids beyond what weight loss alone explains.

5) Be aware of possible changes in energy and mental clarity

• Some retatrutide users report alertness, clarity, and more “activated” energy.
• Suggested mechanism: higher ketones can serve as brain-signaling fuels and may support focus.
• Nuance: this isn’t universal—some people feel neutral or fatigued early.

6) Treat insulin resistance as a core lever for long-term results

• The subtitles emphasize insulin sensitivity/resistance as central to metabolic health.
• Claimed trial outcomes:
  • Fasting insulin down (up to ~71%)
  • HOMA-IR improved (nearly ~70%)
• Practical implication (described): improved insulin signaling may restore metabolic flexibility—the ability to use fat stores when needed.

---

Source / Presenter(s)

• Dr. Jones (DC) — presenter; leads the coaching department at a nationwide GLP-1 & peptide clinic (as stated in the subtitles).